AZTR (Azitra, Inc.) Multiplikator Forward P/S

The implementation of automated bioreactors to eliminate contamination during protein synthesis is impacting share prices, and the forward P/S history on GURU.Markets reflects this trend, where 327.50 becomes the new value for the metric. Strategic alliances with research centers enhance the M&A attractiveness of Azitra, Inc., while the application of unique microbiome technologies allows the company to exercise pricing power by setting premium prices for dermatological drugs.

The forward P/S ratio compares the market capitalization of Azitra, Inc. (AZTR) with expected sales volume, allowing investors to determine the extent of the premium paid for future cash flows. By analyzing the forward P/S valuation, one can assess the fundamental value of the assets in the absence of geopolitical risks and sanctions pressure, which makes the multiplier's dynamics a pure reflection of the efficiency of developing skin microbiome-based drugs.